Ovid Therapeutics Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. Welcome to Earnings Valhalla. By using this site you agree to the
For the third quarter, Ovid Therapeutics had an EPS of $0.28, compared to year-ago quarter EPS of $0.43. Currency in USD, Trade prices are not sourced from all markets. No changes to the price of Ovid Therapeutics Inc stock on the last trading day (Wednesday, 10th Feb 2021). For the best MarketWatch.com experience, please update to a modern browser. Ovid Therapeutics (OVID) news for Wednesday concerning results from a recent clinical trial have OVID stock taking a beating. For more information about the NASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI.About Ovid TherapeuticsOvid Therapeutics Inc. is a New York-based biopharmaceutical company using its BoldMedicine® approach to develop medicines that transform the lives of patients with rare neurological disorders. In March and again in June, Ladenburg Thalmann analyst Michael Higgins gave the stock a $20 price target. Create a list of the investments you want to track. Ovid Therapeutics (NASDAQ:OVID) Price Target and Consensus Rating 9 Wall Street analysts have issued ratings and price targets for Ovid Therapeutics in the last 12 months. All quotes are in local exchange time. For example, although Amazon.com made... NEW YORK, Dec. 16, 2020 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurological diseases, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI). Their forecasts range from $4.00 to $40.00. Ovid prices $50M stock offering at $8 per share SA NewsTue, Aug. 25, 2020 8 Comments Ovid's soticlestat successful in mid-stage study in severe forms of childhood epilepsy SA NewsTue, Aug. 25, ⦠During the day the stock fluctuated 11.93% from a day low at $3.27 to a day high of $3.66. The NASDAQ Biotechnology Index is re-ranked annually and all securities in the index are listed on the NASDAQ Global Market or the NASDAQ Global Select Market, and meet minimum market value and share volume requirements among other criteria. Barron's also provides information on historical stock ratings, target prices, company earnings, market ⦠Why Its Stock Is a Buy. Something went wrong while loading Watchlist. In addition, options based on the iShares NASDAQ Biotechnology Index Fund trade on various exchanges. Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Even after its recent rally, though, Ovid ⦠Price target in 14 days: 4.513 USD. All rights reserved. This browser is no longer supported at MarketWatch. 9 Wall Street analysts have issued 1 year target prices for Ovid Therapeutics' stock. Visit a quote page and your recently viewed tickers will be displayed here. Subscriber Agreement & Terms of Use,
Ovid Therapeutics, Inc. focuses on developing medicines for patients and families living with rare neurological disorders. Date Requested Closing Price Volume Split Adjustment Factor Open Price Day High Day Low; Feb 16, 2021: $3.75: 5,395,045: 1:1: $3.48: $3.97: $3.33 In depth view into OVID (Ovid Therapeutics) stock including the latest price, news, dividend history, earnings information and financials. Ovid Therapeutics Inc. Common Stock (OVID) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Ovid Therapeutics is estimated to decline in value after the ⦠Subscribe to Premium to view Fair Value for OVID. The addition will become effective prior to market open on Monday, December 21, 2020. Real time Ovid Therapeutics Inc. (OVID) stock price quote, stock graph, news & analysis. U.N. Panel of Experts alleges Blackwater founder and Trump ally Erik Prince breached Libya arms embargo, says diplomat. But Equity Investors Don’t Seem to Care. Read More The listed name for OVID is Ovid Therapeutics Inc. Common Stock. Big Pharma and Biotech Need to Do More in the Fight Against Covid-19, Ovid Therapeutics, Sunrun, Pure Cycle, and Other 13D Filings, William Blair Thinks Ovid Therapeutics’ Stock is Going to Recover, Ovid Therapeutics News: Why OVID Stock Is Plunging 55% Today. Stock analysis for Ovid therapeutics Inc (OVID:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. PayPal Stock Passes Mastercard and Looks to a High-Growth Future. Intraday Data provided by FACTSET and subject to terms of use. The NASDAQ Biotechnology Index is the basis for the iShares NASDAQ Biotechnology IndexSM Fund. The price ⦠View daily, weekly or monthly format back to when Ovid Therapeutics Inc. stock was issued. Their average twelve-month price target is $12.57, ⦠The Company is developing OV935 (soticlestat) in collaboration with Takeda Pharmaceutical Company Limited, which is expected to initiate its pivotal clinical trials in 2021 for the potential treatment of rare developmental and epileptic encephalopathies (DEEs). Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock NEW YORK, Oct. 04, 2019 (GLOBE NEWSWIRE) -- ⦠The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB). © 2021 Verizon Media. Are Options Traders Betting on a Big Move in Ovid Therapeutics (OVID) Stock? View the latest Ovid Therapeutics Inc. (OVID) stock price, news, historical charts, analyst ratings and financial information from WSJ. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. The entity has historical hype elasticity of -0.1 and average elasticity to hype of competition of -1.03. View today's stock price, news and analysis for Ovid Therapeutics Inc. (OVID). This time it may be different. Ovid Therapeutics Inc is in the bottom half of stocks based on the fundamental outlook for the stock and an analysis of the stock⦠Get today's Ovid Therapeutics Inc stock price and latest OVID news as well as Ovid Therapeutics real-time stock quotes, technical analysis, full financials and more. Ovid Therapeutics Announces Pricing of $32.5 Million of Securities in Concurrent Public Offerings of Common Stock and Preferred Stock Globenewswire Test -26.76% 08:30AM Copyright © 2021 MarketWatch, Inc. All rights reserved. OVID | Complete Ovid Therapeutics Inc. stock news by MarketWatch. Discover historical prices for OVID stock on Yahoo Finance. What this means: InvestorsObserver gives Ovid Therapeutics Inc (OVID) an overall rank of 37, which is below average. Ovid Therapeutics Stock Forecast, OVID stock price prediction. We can readily understand why investors are attracted to unprofitable companies. Log in to see them here or sign up to get started. OVID is evaluating the results of the NEPTUNE trial of OV101 (gaboxadol) for the treatment of Angelman syndrome and Fragile X syndrome. Have Watchlists? RBC Capital Reaffirms Their Buy Rating on Ovid Therapeutics (OVID). The company was founded by Matthew During in April 2014 and is headquartered in New York, NY. Ovid Therapeutics Inc. Common Stock (OVID) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. There are currently no items in this Watchlist. On average, they anticipate Ovid Therapeutics' stock price to reach $12.57 in ⦠Oracle Is Turning Into a Cloud Giant. Privacy Notice, and
Ovid Therapeutics (OVID) Gets a Buy Rating from Ladenburg Thalmann & Co. Ovid Therapeutics (OVID) Jumps: Stock Rises 12.4%, Implied Volatility Surging for Ovid Therapeutics (OVID) Stock Options, Top Ranked Momentum Stocks to Buy for April 22nd, Inovio (INO) Stock Up YTD on Coronavirus Vaccine Efforts, Gilead, Bristol-Myers Pumped More Into R&D Than Shareholder Enrichments. Yes, Rates Are Rising. The stock has a 52-week-high of 9.4 and a 52-week-low of 1.8. The company was founded by Matthew During in April 2014 and is headquartered in New York, NY. Find real-time OVID - Ovid Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Endowments Took a Double Blow from the Pandemic: Lost Revenues and Falling Stocks. Pharma Company Buybacks: Do They Really Benefit Shareholders. We are […], Discover new investment ideas by accessing unbiased, in-depth investment research, NasdaqGS - NasdaqGS Real Time Price. Intraday data delayed at least 15 minutes or per exchange requirements. OVID: Get the latest Ovid Therapeutics stock price and detailed information including OVID news, historical charts and realtime prices.
Ovid Therapeutics is now traded for 2.61. Tech Valuations Are Getting Scary. View OVID THERAPEUTC OVID investment & stock information. Why Stocks Can Still Shine. View real-time stock prices and stock quotes for a full financial overview. Cookie Notice (). They Still Have Room to Run. OVID THERAPEUTICS (NASDAQ:OVID) PRICE TARGET AND CONSENSUS RATING: stockguard: 11/03/19 04:54:09 PM #6 Ovid Therapeutics Announces Senior Management Promotions in ⦠Historical and current end-of-day data provided by FACTSET. Bausch Health, Qualtrics See Activist Action. OVID - Ovid Therapeutics Inc Stock quote - CNNMoney.com Markets Bank Stocks Are Getting Hot. Get the latest OVID THERAPEUTC OVID detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. Here’s How We Know. For more information on Ovid, please visit www.ovidrx.com.ContactsInvestors and Media: Ovid Therapeutics Inc. Investor Relations & Public Relations irpr@ovidrx.comORInvestors: Argot Partners Maeve Conneighton/Dawn Schottlandt 212-600-1902 ovid@argotpartners.comMedia: Dan Budwick 1AB dan@1abmedia.com, Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. OVID, Ovid Therapeutics Inc - Stock quote performance, technical chart analysis, SmartSelect Ratings, Group Leaders and the latest company headlines